EVOTF
Evotec SE
$6.69
0.00%
No data for this timeframe.
Vol
SEC Reports5
Recent Activity
May 6, 2026
SEC
Evotec SE reported Q1 2026 results with a 22% revenue decline to €156.6M and Adjusted EBITDA swinging to -€21.9M from +€
6-K — Impact 6/10
Apr 30, 2026
SEC
Evotec announced the nomination of Dr. Wolfgang Hofmann as an independent Supervisory Board member and entered into a co
6-K — Impact 4/10
Apr 8, 2026
SEC
Evotec reported full-year 2025 results with €788.4 million in revenue, a slight decline from 2024, but a significant inc
6-K — Impact 6/10
Analyst Ratings
2Strong Buy
5Buy
5Hold
0Sell
0Strong Sell
Latest Reports
BEARISH
6-K
6/10
Evotec SE reported Q1 2026 results with a 22% revenue decline to €156.6M and Adjusted EBITDA swinging to -€21.9M from +€
May 6, 2026
NEUTRAL
6-K
4/10
Evotec announced the nomination of Dr. Wolfgang Hofmann as an independent Supervisory Board member and entered into a co
Apr 30, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 2 mixed, 1 neutral. Avg impact: 6.0/10.
BEARISH
6-K
6/10
Evotec SE reported Q1 2026 results with a 22% revenue decline to €156.6M and Adjusted EBITDA swingin
May 6, 2026
NEUTRAL
6-K
4/10
Evotec announced the nomination of Dr. Wolfgang Hofmann as an independent Supervisory Board member a
Apr 30, 2026
MIXED
6-K
6/10
Evotec reported full-year 2025 results with €788.4 million in revenue, a slight decline from 2024, b
Apr 8, 2026
MIXED
20-F
7/10
Evotec's 20-F filing confirms a strategic transformation with the 'Horizon' initiative, which includ
Apr 8, 2026
BULLISH
6-K
7/10
Evotec announced two material events: the nomination of Dieter Weinand as Chairman of its Supervisor
Apr 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 58% buy across 12 analysts — 2 strong buy, 5 buy, 5 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.2B | 2.4% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.2B | 17.1% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.7B | -6.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.8B | 10.9% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 5 | 0 | 0 | 58% | |
| May 1, 2026 | 3 | 5 | 5 | 0 | 0 | 62% | |
| Apr 1, 2026 | 3 | 5 | 5 | 0 | 0 | 62% | |
| Mar 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Feb 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Jan 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.